Abstract
Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Current Drug Delivery
Title:Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery
Volume: 11 Issue: 2
Author(s): Priyanka Pahuja, Heena Kashyap and Pravin Pawar
Affiliation:
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Abstract: Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Export Options
About this article
Cite this article as:
Pahuja Priyanka, Kashyap Heena and Pawar Pravin, Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/1567201810666131224105205
DOI https://dx.doi.org/10.2174/1567201810666131224105205 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Use of Antihistamines in Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Manipulation of Intracellular pH in Cancer Cells by NHE1 Inhibitors
Protein & Peptide Letters Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrhythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Overview of Periodic Safety Update Reports: Where Have We Reached?
Applied Clinical Research, Clinical Trials and Regulatory Affairs A Review of Feature Extraction from ECG Signals and Classification/ Detection for Ventricular Arrhythmias
Recent Advances in Computer Science and Communications Medical Therapy for Long QT Syndrome
Mini-Reviews in Medicinal Chemistry Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Drug-Induced Hypokalaemia
Current Drug Safety Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology The Enigmatic Drug Binding Site for Sodium Channel Inhibitors
Current Molecular Pharmacology Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry